Green Thumb Plows Another $50 Million Into Buying Its Own Stock — But Can Buybacks Alone Fix a Cannabis Valuation Problem?
Shares of Green Thumb Industries surged 10.7% to $8.09 on September 24, sharply outperforming a weaker broader market, after the cannabis giant launched a fresh $50 million, 12-month share-repurchase program on September 23. The move extends what has become one of the most aggressive capital-return strategies in the U.S. cannabis sector — and raises the question of whether management is genuinely buying undervalued stock or simply propping up a price that the market refuses to reward.
• The Company Has Already Spent $200 Million Buying Back Its Own Shares. Under its previous repurchase programs dating back to September 2023, Green Thumb bought back roughly 29.5 million shares for $203.4 million.
More than $80 million of those repurchases occurred in 2026 alone. At current prices, the new $50 million authorization could retire roughly 6.2 million additional shares — meaningful when approximately 195.1 million subordinate voting shares were outstanding as of June 30.
• The Balance Sheet Can Handle It — For Now. Cash at the end of Q2 totaled $283.6 million, and the company does not expect to incur debt to fund the program.
Q1 alone produced normalized EBITDA (operating profit before non-cash charges) of $93.5 million on $300 million in revenue, while Q2 cash flow from operations slowed to $29 million — a dip management attributed to increased investment in its workforce, a deliberate decision to retain and reward employees. The buyback is comfortable but not costless: spending $50 million leaves less room for store expansion or acquisitions in an industry still consolidating.
• Buybacks Haven't Stopped the Slide. Despite retiring nearly 30 million shares over three years, GTBIF traded around $7.30 for most of the past week — well below the Q1 average repurchase price of $5.51 and the Q2 average of $6.11. That means the stock has actually risen above management's recent buy levels, partially vindicating the strategy, but the broader downtrend since 2021 underscores that buybacks alone cannot substitute for revenue acceleration or a U.S. stock-exchange listing.
• The Real Catalyst May Be Regulatory, Not Financial. In April 2026, the DOJ issued a final order rescheduling medical marijuana to Schedule III, and Green Thumb is pursuing a clear path toward a U.S. exchange uplisting. An uplisting would expose the stock to institutional capital currently barred from OTC cannabis names — a structural unlock no buyback can replicate.